Clinical Research in Cardiology

, Volume 101, Issue 7, pp 585–591 | Cite as

The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina

  • Michal TenderaEmail author
  • Ewa Gaszewska-Żurek
  • Zofia Parma
  • Piotr Ponikowski
  • Ewa Jankowska
  • Kalina Kawecka-Jaszcz
  • Danuta Czarnecka
  • Maria Krzemińska-Pakuła
  • Zbigniew Bednarkiewicz
  • Maciej Sosnowski
  • Michael Ochan Kilama
  • Rahul Agrawal
Original Paper



Anti-ischaemic effect of A1 adenosine receptor agonists was shown in animal and preclinical studies. The present proof-of-concept study aimed at evaluation of the efficacy and safety of a new adenosine A1 receptor agonist capadenoson in patients with stable angina.


This was a randomized, double-blind, placebo-controlled, single dose-escalating, multicenter trial comparing the effect of capadenoson at 1, 2.5, 5, 10, and 20 mg versus placebo. For each dose step patients were randomized to receive single doses of either capadenoson or matching placebo in a 5:1 ratio. The primary efficacy variable was the absolute difference in heart rate (HR) at maximum comparable level of workload between baseline and post dose exercise tolerance test at maximum concentration of capadenoson. Capadenoson effect on total exercise time and time to 1-mm ST-segment depression were also measured.


Sixty-two male patients with stable angina were enrolled in the study. There was a consistent trend for HR reduction at comparable maximum work load in active treatment groups, with significant differences against placebo for 10 and 20 mg (HR reduction by 12.2 and 6.8 beats per min, p = 0.0002 and p = 0.032, respectively). A statistically significant trend (p = 0.0003) for a reduction in HR with increasing doses of capadenoson was shown. Increases in total exercise time and time to 1-mm ST-segment depression were also observed.


In patients with stable angina capadenoson lowers exercise HR at comparable maximum workload, which is associated with improved total exercise time and prolongation of time to ischaemia.


Coronary artery disease Stable angina Capadenoson A1 receptor agonists Heart rate Exercise testing 



The study was funded by Bayer Schering Pharma, Wuppertal, Germany.


  1. 1.
    Fox K, Garcia MAA, Ardissino D et al (2006) Task force on the management of stable angina pectoris of the European Society of Cardiology. Guidelines for the management of stable angina pectoris. Eur Heart J 27:1341–1381PubMedCrossRefGoogle Scholar
  2. 2.
    Borer JS, Fox K, Jaillon PP, Lerebours G (2003) Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina. A randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107:817–823PubMedCrossRefGoogle Scholar
  3. 3.
    Tardif JC, Ford I, Tendera M, Bourassa MG, INITIATIVE Investigators (2005) Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26:2529–2536PubMedCrossRefGoogle Scholar
  4. 4.
    Liu Y, Yang X, Yang XM, Walker S, Förster K, Cohen MV, Krieg T, Downey JM (2010) AMP579 is revealed to be a potent A2b-adenosine receptor agonist in human 293 cells and rabbit hearts. Basic Res Cardiol 105:129–137PubMedCrossRefGoogle Scholar
  5. 5.
    Koester R, Kaehler J, Meinertz T (2011) Ivabradine for the treatment of stable angina pectoris in octogenarians. Clin Res Cardiol 100:121–126PubMedCrossRefGoogle Scholar
  6. 6.
    Koester R, Kaehler J, Ebelt H, Soeffker G, Werdan K, Meinertz T (2010) Ivabradine with combination with beta-blocker therapy for the treatment of stable angina pectoris in every day clinical practice. Clin Res Cardiol 99:665–672PubMedCrossRefGoogle Scholar
  7. 7.
    Hjalmarson A, Gilpin EA, Kjekshus J et al (1990) Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 65:547–553PubMedCrossRefGoogle Scholar
  8. 8.
    Fox K, Ford I, Steg PG, Tendera M, Robertson M, BEAUTIFUL investigators (2008) Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372:817–821PubMedCrossRefGoogle Scholar
  9. 9.
    Yan L, Burbiel J, Maass A, Mueller CE (2003) Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs 8:537–576PubMedCrossRefGoogle Scholar
  10. 10.
    Belardinelli L, Shryock J, Song Y, Wang D, Srinivas M (1995) Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes. FASEB J 9:359–365PubMedGoogle Scholar
  11. 11.
    Dhalla A, Shryock J, Shreenivas R, Belardinelli L (2003) Pharmacology and therapeutic applications of A1 adenosine receptor ligands. Curr Top Med Chem 3:369–385PubMedCrossRefGoogle Scholar
  12. 12.
    Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, Downey JM (1991) Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 84:350–356PubMedCrossRefGoogle Scholar
  13. 13.
    Auchampack JA, Gross GJ (1993) Adenosine A1 receptors, KATP channels and ischaemic preconditioning in dogs. Am J Physiol 264:H1327–H1336Google Scholar
  14. 14.
    Zablocki JA, Wu L, Shryock J, Belardinelli L (2004) Partial A1 adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation. Curr Top Med Chem 4:839–854PubMedCrossRefGoogle Scholar
  15. 15.
    Frey R, Mueck W, Delesen H (2006) Single dose, basic phase I dose-escalation study in a randomized, single-blind, placebo-controlled, group comparison design to investigate safety and tolerability of BAY 68-4986 and its pharmacodynamics and pharmacokinetics after oral dosing in 8 healthy male subjects per dose step. Internal Archive, Report Number PH-34381Google Scholar
  16. 16.
    Shewan LG, Coats AJ (2010) Ethics in the authorship and publishing of scientific articles. Int J Cardiol 144:1–2CrossRefGoogle Scholar
  17. 17.
    Baraldi PG, Cacciari B, Romagnoli R, Spalluto G (1999) A1 and A3 adenosine receptor agonists: an overview. Exp Opin Ther Patents 9:515–527CrossRefGoogle Scholar
  18. 18.
    Elzein E, Zablocki J (2008) A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs 17:1901–1910PubMedCrossRefGoogle Scholar
  19. 19.
    Higgins MJ, Hosseinzadeh H, MacGregor DG, Ogilvy H, Stone TW (1994) Release and actions of adenosine in the central nervous system. Pharm World Sci 16:62–68PubMedCrossRefGoogle Scholar
  20. 20.
    Press NJ, Gessi S, Borea PA, Polosa R (2007) Therapeutic potential of adenosine receptor antagonists and agonists. Expert Opin Ther Pat 17:979–991PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Michal Tendera
    • 1
    Email author
  • Ewa Gaszewska-Żurek
    • 1
  • Zofia Parma
    • 1
  • Piotr Ponikowski
    • 2
  • Ewa Jankowska
    • 2
  • Kalina Kawecka-Jaszcz
    • 3
  • Danuta Czarnecka
    • 3
  • Maria Krzemińska-Pakuła
    • 4
  • Zbigniew Bednarkiewicz
    • 4
  • Maciej Sosnowski
    • 1
  • Michael Ochan Kilama
    • 6
  • Rahul Agrawal
    • 5
  1. 1.Third Division of CardiologyMedical University of SilesiaKatowicePoland
  2. 2.Medical AcademyWroclawPoland
  3. 3.Collegium MedicumJagiellonian UniversityKrakowPoland
  4. 4.Medical UniversityLodzPoland
  5. 5.Bayer HealthCareWuppertalGermany
  6. 6.Bayer HealthCareMilanItaly

Personalised recommendations